The approval comes less than a year Bristol Myers Squibb paid $14 billion to acquire the developer of the drug, Karuna ...

A meta-analysis reveals gamified digital mental health interventions effectively reduce depression and ADHD in youth, ...

US poised to approve KarXT as new antipsychotic treatment for disorder, which could offer reduced side-effects ...

Cobenfy is the first FDA-approved antipsychotic that targets cholinergic receptors instead of dopamine receptors.

Research suggests that doctors can help patients reduce pain by giving them virtual reality games to play during medical ...

Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than ...

The drugmaker is banking on the treatment to help power growth as patents on its ... psychiatry professor at Stanford ...

A contract for the running of a youth alcohol and other drug rehabilitation centre has been awarded to a Far North ...

In newly released data, lenacapavir, given via a twice-yearly injection, has shown remarkable effectiveness at eliminating ...

“ [The] first rehab I went to was like university on how to be a better drug addict,” Osbourne recalled. “I’d learned so many ...

A new dose-finding study supported the potential of the carbonic anhydrase inhibitor as an alternative to CPAP machines.